Top Headlines
Latest News
Analysis
Antibodies containing two binding sites – bispecifics – are hot items these days generating a great deal of buzz in the industry. This is due to the fact that many of the new therapeutics now in development based on this technology hold much promise due to their synergistic effects conferred by binding two targets.
Our Habitat for All Things Science
Trials With ABT-199 Held Up; Patient Death on AbbVie Drug?
Backing up the European approval of Humira (adalimumab) with more data, Abbott spinout AbbVie for the first time offered long-term, patient-reported health outcomes data from the Phase III IMAgINE-1 trial in young people with Crohn's disease, along with favorable results of a caregiver survey.
- Regenerative Medicine Taking on Severe Facial Injuries »
- False T-Cell Memories May Aid the Immune Response »
- Taking out Exporter is Double Whammy for S. aureus Toxins »
- Scientists Direct Focus on Targeting Short-Sight Genes »
- Inflammation Mouse Models Suggest New Strategies Needed »
- Passenger Mutations: Cancer's Backseat and Backward Drivers »
- With Unique MOA, HER4 Joins EGFR Family Cancer Targets »
- Control of Cancer, Not Killing, Is Key to Treatment: Study »
- Sirt3 Activation Reverses Aging of Blood Stem Cells »
Upcoming conferences
Opinion
- Patients Take the Lead in Clinical Whole Genome SequencingFebruary 12, 2013 | 4:17 PM | Posted by: Catherine Shaffer
- ‘Fast’ Progress: Ampligen Activist Ends Hunger StrikeFebruary 12, 2013 | 10:50 AM | Posted by: Randy Osborne
- On the ‘Gom-Boo,’ Ampligen, and Holding Out HopeFebruary 07, 2013 | 3:12 PM | Posted by: Randy Osborne
- Don’t Call Them Generics!January 29, 2013 | 4:19 PM | Posted by: Mari Serebrov
- Biosimilars are Changing the Global GameJanuary 23, 2013 | 10:01 AM | Posted by: Mari Serebrov
